Abivenir

/ BioAvenir Ltd.

The usual dosage is generally 4 tablets of Abiraterone 250 mg daily (1,000 mg per day).
For metastatic castration-resistant prostate cancer (CRPC), take Abiraterone 250 mg together with 5 mg prednisone twice daily.
For metastatic hormone-sensitive prostate cancer (mHSPC), take Abiraterone 250 mg together with 5 mg prednisone daily.

* Metastatic castration-resistant prostate cancer.
* Adult males with newly diagnosed high risk metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).

* Hypersensitivity to Abiraterone or to any other of the additional ingredients.
* Woman (especially a pregnant woman)
* Severe liver damage
* In combination with Ra-223 (which is used to treat prostate cancer).

Please refer to the license holder for further details.

Very common: edema, low blood potassium level, increased in liver function values, high blood pressure, urinary tract infection, diarrhea.
Common: hypertriglyceridemia, chest pain, atrial fibrillation, heart failure, tachycardia, sepsis, bone fractures, indigestion, hematuria, Rash.
Please refer to the license holder for further details.

Please refer to the license holder for further details.

Abiraterone is not intended for use in women.
Pregnancy:
This medicine may harm the fetus if taken during pregnancy.
Women who are pregnant or may become pregnant should wear gloves if they come into contact with Abiraterone A man who has sexual intercourse with a woman who could become pregnant should use a condom and another effective contraceptive measure.
A man who has sexual intercourse with a pregnant woman should use a condom to protect the fetus.
Lactation: Please refer to the license holder for further details.   

Please refer to the license holder for further details.